Patrick Grohar Laboratory
The Grohar Laboratory employs a bench to bedside approach to develop targeted therapies for pediatric solid tumors. The Grohar lab has primarily focused on the therapeutic targeting of EWS-FLI1 for Ewing sarcoma. EWS-FLI1 is the defining molecular lesion of Ewing sarcoma and multiple independent studies have established a dependence of the tumor on the continued activity of EWS-FLI1. However, EWS-FLI1 is a transcription factor and widely regarded as a challenging if not “undruggable” target. Our overarching goal is to identify novel therapies that target EWS-FLI1. To accomplish this, we employ a combination of unbiased screening approaches and mechanistic pharmacology to identify and interrogate therapeutic vulnerabilities that arise from EWS-FLI1 driven transcription. These efforts will allow us to translate therapies to the clinic more effectively and extend our findings to other tumors that depend on similar molecular targets.
Collaborators of the Patrick Grohar Laboratory from outside of the Center for Childhood Cancer Research include Sarah Cherry, (University of Pennsylvania), David Schultz, (University of Pennsylvania), and Robert G. Maki, MD, PhD (University of Pennsylvania).